Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality inwomenwith stage I-III breast cancer: A nationwide population-based cohort study

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4065-4077

  Barron, Thomas I ^a,d   Flahavan, Evelyn M ^a   Sharp, Linda ^b   Bennett, Kathleen ^a   Visvanathan, Kala ^c,d  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; FEMALE; HUMAN; IRELAND; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME; BREAST TUMOR; EPIDEMIOLOGY; LYMPH NODE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BREAST NEOPLASMS; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; IRELAND; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905453311     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2679     Document Type: Article

References (58)

1. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
2. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72.
3. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007;101:191-7.
4. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012;21:181-95.
5. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012;92:1115-28.
6. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
7. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 2011;130:657-62.
8. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011;29:2635-44.
9. BreastCheck The National Breast Screening Programme History [Internet]. [cited 2012 Oct. 17]. Available from: http://www.breastcheck.ie/content/history.
10. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJM, van Herk-Sukel MPP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012;106:1564-70.
11. Bulliard J-L, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effectiveness of organised versus opportunistic mammography screening. Ann Oncol 2009;20:1199-202.
12. NCRI. Data Quality and Completeness at the Irish National Cancer Registry [Internet]. 2012 [cited 2013 Nov. 23]. Available from: http://www.ncri.ie/pubs/ pubfiles/CompletenessQuality.pdf.
13. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
14. Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45:S131-42.
15. Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996;40:75-86.
16. WHO. ATC classification index with DDDs, 2011. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2010.
17. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen Y-L, Pytowski B, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006;66:8065-75.
18. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
19. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
20. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol 1998;27:91-5.
21. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 1986;123:174-84.
22. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199-200.
23. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol 1987;125:761-8.
24. Bevilacqua J, Cody H III, MacDonald KA, Tan LK, Borgen PI, Van Zee KJ. A prospective validated model for predicting axillary node metastases based on 2, 000 sentinel node procedures: the role of tumour location [corrected]. Eur J Surg Oncol 2002;28:490-500.
25. Gann PH, Colilla SA, Gapstur SM, Winchester DJ, Winchester DP. Factors associated with axillary lymph node metastasis from breast carcinoma: descriptive and predictive analyses. Cancer 1999;86:1511-9.
26. Reyal F, Rouzier R, Depont-Hazelzet B, Bollet MA, Pierga J-Y, Alran S, et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS ONE 2011;6:e20297.
27. Daniell HW. Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer 1988;62:429-35.
28. Bucchi L, Barchielli A, Ravaioli A, Federico M, De Lisi V, Ferretti S, et al. Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. Br J Cancer 2005;92:156-61.
29. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010;70:7042-52.
30. Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate- induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol 2010;160:1195-211.
31. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
32. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48.
33. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, et al. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer 2002;87:231-7.
34. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 2004;19:741-56.
35. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer 2006;42:1077-82.
36. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
37. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12.
38. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
39. Botto LD, Khoury MJ. Commentary: facing the challenge of geneenvironment interaction: the two-by-four table and beyond. Am J Epidemiol 2001;153:1016-20.
40. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol 2012;41:514-20.
41. Denkert C, Winzer K-J, Müller B-M, Weichert W, Pest S, Köbel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
42. Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-82.
43. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 2013;105:1456-62.
44. Zhang X, Loberiza FR, Klein JP, Zhang M-J. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007;88:95-101.
45. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Lowdose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer 2013;109:1921-5.
46. Ljung R, Sennerstam R, Mattsson F, Auer G, Lagergren J. Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis. Int J Cancer 2014;135:238-41.
47. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012;30:3468-77.
48. Cook NR, Lee I-M, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
49. Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.
50. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U. S.cohort. Cancer Epidemiol Biomarkers Prev 2005;14:261-4.
51. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-93.
52. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-12.
53. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2008;109:533-43.
54. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
55. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
56. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:1033-41.
57. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 2011;20:131-7.
58. Jurek AM, Greenland S, Maldonado G, Church TR. Proper interpretation of non-differential misclassification effects: expectations vs observations. Int J Epidemiol 2005;34:680-7.